AR126038A1 - Composición farmacéutica que comprende anticuerpos específicamente unidos a la proteína asm como ingrediente activo para tratar enfermedades cerebrales - Google Patents
Composición farmacéutica que comprende anticuerpos específicamente unidos a la proteína asm como ingrediente activo para tratar enfermedades cerebralesInfo
- Publication number
- AR126038A1 AR126038A1 ARP220101397A ARP220101397A AR126038A1 AR 126038 A1 AR126038 A1 AR 126038A1 AR P220101397 A ARP220101397 A AR P220101397A AR P220101397 A ARP220101397 A AR P220101397A AR 126038 A1 AR126038 A1 AR 126038A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- positions
- asm
- protein
- antibody
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 208000014644 Brain disease Diseases 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 8
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se revela el uso de un anticuerpo o fragmento de unión antígeno del mismo que se une específicamente a una proteína del ácido esfingomielinasa (ASM), donde el anticuerpo o fragmento de unión antígeno del mismo se une específicamente a una proteína ASM con alta afinidad, inhibe significantemente la actividad de la proteína ASM presente en la membrana celular y muestra efectos de mejora de la memoria cognitiva, inhibiendo la actividad de la proteína ASM, inhibiendo la acumulación de proteínas amiloide-b y tau e inhibiendo la producción de neuroinflamación aún sin toxicidad en modelos animales con enfermedad de Alzheimer, y así puede usarse ventajosamente en el tratamiento de una enfermedad cerebral. Reivindicación 1: Una composición farmacéutica para prevenir o tratar una enfermedad cerebral, la composición farmacéutica caracterizada porque comprende como un ingrediente activo un anticuerpo o fragmento de unión antígeno del mismo que específicamente se une a una proteína de ácido esfingomielinasa (ASM). Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque el anticuerpo o fragmento de unión antígeno del mismo se une a por lo menos un epítopo seleccionado del grupo que consiste en: un fragmento de aminoácidos en las posiciones 53 a 72, un fragmento de aminoácidos en las posiciones 101 a 123, un fragmento de aminoácidos en las posiciones 135 a 159, un fragmento de aminoácidos en las posiciones 135 a 155, un fragmento de aminoácido en las posiciones 218 a 228, y un fragmento de aminoácidos en las posiciones 259 a 269 del termino N de la proteína ASM. Reivindicación 3: La composición farmacéutica de la reivindicación 1, caracterizada porque el anticuerpo o fragmento de unión antígeno del mismo se une a por lo menos un epítopo seleccionado del grupo que consiste de polipéptidos especificados en la SEC ID Nº 68 a 73, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210068628 | 2021-05-27 | ||
| KR1020220057049A KR20220160483A (ko) | 2021-05-27 | 2022-05-10 | Asm 단백질에 특이적으로 결합하는 항체를 유효성분으로 포함하는 뇌질환 치료용 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126038A1 true AR126038A1 (es) | 2023-09-06 |
Family
ID=84228972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101397A AR126038A1 (es) | 2021-05-27 | 2022-05-26 | Composición farmacéutica que comprende anticuerpos específicamente unidos a la proteína asm como ingrediente activo para tratar enfermedades cerebrales |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4349865A1 (es) |
| JP (1) | JP7484028B1 (es) |
| AR (1) | AR126038A1 (es) |
| AU (1) | AU2022279866A1 (es) |
| BR (1) | BR112023024632A2 (es) |
| CA (1) | CA3219114A1 (es) |
| CO (1) | CO2023016081A2 (es) |
| IL (1) | IL308738A (es) |
| MX (1) | MX2023014103A (es) |
| WO (1) | WO2022250470A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242529B2 (en) * | 2013-05-07 | 2022-02-08 | Kyungpook National University Industry-Academic Cooperation Foundation | Method for treating a neurological disorder comprising administering ASM inhibitors |
| KR101521117B1 (ko) | 2013-05-07 | 2015-05-18 | 경북대학교 산학협력단 | Ａｓｍ 억제제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
-
2022
- 2022-05-26 BR BR112023024632A patent/BR112023024632A2/pt unknown
- 2022-05-26 AU AU2022279866A patent/AU2022279866A1/en active Pending
- 2022-05-26 EP EP22811661.2A patent/EP4349865A1/en active Pending
- 2022-05-26 CA CA3219114A patent/CA3219114A1/en active Pending
- 2022-05-26 WO PCT/KR2022/007485 patent/WO2022250470A1/ko active Application Filing
- 2022-05-26 MX MX2023014103A patent/MX2023014103A/es unknown
- 2022-05-26 JP JP2023572865A patent/JP7484028B1/ja active Active
- 2022-05-26 IL IL308738A patent/IL308738A/en unknown
- 2022-05-26 AR ARP220101397A patent/AR126038A1/es unknown
-
2023
- 2023-11-23 CO CONC2023/0016081A patent/CO2023016081A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022250470A1 (ko) | 2022-12-01 |
| TW202246355A (zh) | 2022-12-01 |
| MX2023014103A (es) | 2023-12-11 |
| CO2023016081A2 (es) | 2023-12-11 |
| BR112023024632A2 (pt) | 2024-02-27 |
| CA3219114A1 (en) | 2022-12-01 |
| EP4349865A1 (en) | 2024-04-10 |
| AU2022279866A1 (en) | 2023-12-14 |
| JP7484028B1 (ja) | 2024-05-15 |
| JP2024521163A (ja) | 2024-05-28 |
| IL308738A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| León et al. | Current technology for the industrial manufacture of snake antivenoms | |
| Haselmann et al. | Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction | |
| ES2346408T3 (es) | Inhibidores y/o antagonista de la proteina hmgb1 destinados al tratamiento de enfermedades vasculares. | |
| Huang et al. | Glial scar formation occurs in the human brain after ischemic stroke | |
| RU2432364C2 (ru) | ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА | |
| Demidova-Rice et al. | Human platelet-rich plasma-and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo | |
| DE60032486T2 (de) | Prion protein peptide und deren verwendung | |
| CN107847595A (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
| US10570193B2 (en) | Binding moieties for biofilm remediation | |
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
| JP2016065100A (ja) | アルツハイマー病治療方法 | |
| León et al. | Comparative study on the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom | |
| US20200030445A1 (en) | Stable formulations of humanized anti-tau antibody | |
| Willingham et al. | Ultrastructural immunocytochemical localization of calmodulin in cultured cells. | |
| Gibbons et al. | Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease | |
| Rogawski | A new SV2A ligand for epilepsy | |
| Park et al. | Effect of single and double administration of human umbilical cord blood-derived mesenchymal stem cells following focal cerebral ischemia in rats | |
| WO2017192594A1 (en) | Binding moieties for biofilm remediation | |
| WO2016154491A1 (en) | Binding moieties for biofilm remediation | |
| US20200354411A1 (en) | Chimeric Molecule for Targeting c-Myc in Cells | |
| Manso et al. | Expression of a low-molecular-weight (10 kDa) calcium binding protein in glial cells of the brain of the trout (Teleostei) | |
| AR126038A1 (es) | Composición farmacéutica que comprende anticuerpos específicamente unidos a la proteína asm como ingrediente activo para tratar enfermedades cerebrales | |
| US20060216294A1 (en) | Method of modulation | |
| DE102008014880A1 (de) | Antientzündliches Polypeptid |